ADC Therapeutics SA
ADCT Healthcare Biotechnology
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.
Follow ADCT
ADC Therapeutics SA (ADCT) EV/Sales
As of 16 October 2026, ADC Therapeutics SA (ADCT) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −1.3× (November 2023) to 33.9× (December 2021); the current reading is higher than 60% of that period. That is below the Biotechnology industry median of 9.4× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.7× | 274.12% |
| FY2024 | 1.0× | — |
| FY2023 | −0.2× | — |
| FY2022 | 0.4× | (98.93%) |
| FY2021 | 33.9× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.8× | (86.37%) |
| Mar 2026 | 5.8× | 57.09% |
| Dec 2025 | 3.7× | (36.49%) |
| Sep 2025 | 5.9× | 167.64% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KROS Keros Therapeutics, Inc. compare | −1.1× |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| MGNX MacroGenics, Inc. compare | 0.3× |
| ADCT ADC Therapeutics SA | 1.6× |
| CAMP CAMP4 Therapeutics Corporation compare | 26.7× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)